Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia
Status:
Withdrawn
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Tardive dyskinesia (TD) is a disabling, embarrassing and often irreversible iatrogenic
movement disorder that can occur in anyone exposed to drugs that block dopamine receptors,
including first and second generation antipsychotics and antiemetic agents. There is no way
to prevent TD except preventing exposure to the inciting agents and there are no approved
symptomatic therapies. Propranolol is an FDA-approved β-blocker with limited data supporting
its use as a treatment for TD.
The goal of this study is to determine the efficacy of propranolol in the treatment of TD in
a double-blind, cross-over prospective manner. If propranolol is found to be an effective
therapy, it will fulfill a great need in the treatment of TD with a medication that is known
to be safe and inexpensive.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Emory University
Collaborator:
Atlanta Clinical and Translational Science Institute